Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
Open Access
- 5 April 2020
- Vol. 12 (4), 884
- https://doi.org/10.3390/cancers12040884
Abstract
MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.This publication has 33 references indexed in Scilit:
- The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISHBlood, 2019
- False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasmsHaematologica, 2018
- Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid MorphologyThe American Journal of Surgical Pathology, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- MYC impairs resolution of site-specific DNA double-strand breaks repairMutation research. Reviews in mutation research, 2015
- ‘Double‐Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patientsBritish Journal of Haematology, 2014
- c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem CellsCell, 2012
- MYC on the Path to CancerCell, 2012
- c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleusProceedings of the National Academy of Sciences of the United States of America, 2005
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 2002